Literature DB >> 28265000

Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Ying C Li1, Ege T Kavalali2.   

Abstract

Presynaptic nerve terminals are highly specialized vesicle-trafficking machines. Neurotransmitter release from these terminals is sustained by constant local recycling of synaptic vesicles independent from the neuronal cell body. This independence places significant constraints on maintenance of synaptic protein complexes and scaffolds. Key events during the synaptic vesicle cycle-such as exocytosis and endocytosis-require formation and disassembly of protein complexes. This extremely dynamic environment poses unique challenges for proteostasis at synaptic terminals. Therefore, it is not surprising that subtle alterations in synaptic vesicle cycle-associated proteins directly or indirectly contribute to pathophysiology seen in several neurologic and psychiatric diseases. In contrast to the increasing number of examples in which presynaptic dysfunction causes neurologic symptoms or cognitive deficits associated with multiple brain disorders, synaptic vesicle-recycling machinery remains an underexplored drug target. In addition, irrespective of the involvement of presynaptic function in the disease process, presynaptic machinery may also prove to be a viable therapeutic target because subtle alterations in the neurotransmitter release may counter disease mechanisms, correct, or compensate for synaptic communication deficits without the need to interfere with postsynaptic receptor signaling. In this article, we will overview critical properties of presynaptic release machinery to help elucidate novel presynaptic avenues for the development of therapeutic strategies against neurologic and neuropsychiatric disorders.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 28265000      PMCID: PMC5394918          DOI: 10.1124/pr.116.013342

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  344 in total

1.  Rapid reuse of readily releasable pool vesicles at hippocampal synapses.

Authors:  J L Pyle; E T Kavalali; E S Piedras-Rentería; R W Tsien
Journal:  Neuron       Date:  2000-10       Impact factor: 17.173

2.  Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4.

Authors:  Rudi K Tannenberg; Heather L Scott; Anthony E G Tannenberg; Peter R Dodd
Journal:  Neurochem Int       Date:  2006-06-30       Impact factor: 3.921

Review 3.  Multiple vesicle recycling pathways in central synapses and their impact on neurotransmission.

Authors:  Ege T Kavalali
Journal:  J Physiol       Date:  2007-08-09       Impact factor: 5.182

4.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

Review 5.  Synapsins: mosaics of shared and individual domains in a family of synaptic vesicle phosphoproteins.

Authors:  T C Südhof; A J Czernik; H T Kao; K Takei; P A Johnston; A Horiuchi; S D Kanazir; M A Wagner; M S Perin; P De Camilli
Journal:  Science       Date:  1989-09-29       Impact factor: 47.728

6.  α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers.

Authors:  David C DeWitt; Elizabeth Rhoades
Journal:  Biochemistry       Date:  2013-03-27       Impact factor: 3.162

7.  Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles.

Authors:  Emma L Clayton; Nancy Sue; Karen J Smillie; Timothy O'Leary; Nicolai Bache; Giselle Cheung; Adam R Cole; David J Wyllie; Calum Sutherland; Phillip J Robinson; Michael A Cousin
Journal:  Nat Neurosci       Date:  2010-06-06       Impact factor: 24.884

8.  Synaptojanin 1 contributes to maintaining the stability of GABAergic transmission in primary cultures of cortical neurons.

Authors:  A Luthi; G Di Paolo; O Cremona; L Daniell; P De Camilli; D A McCormick
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

9.  DNA variation in the SNAP25 gene confers risk to ADHD and is associated with reduced expression in prefrontal cortex.

Authors:  Ziarih Hawi; Natasha Matthews; Joseph Wagner; Robyn H Wallace; Tim J Butler; Alasdair Vance; Lindsey Kent; Michael Gill; Mark A Bellgrove
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  Asynchronous GABA Release Is a Key Determinant of Tonic Inhibition and Controls Neuronal Excitability: A Study in the Synapsin II-/- Mouse.

Authors:  Lucian Medrihan; Enrico Ferrea; Barbara Greco; Pietro Baldelli; Fabio Benfenati
Journal:  Cereb Cortex       Date:  2014-06-24       Impact factor: 5.357

View more
  17 in total

Review 1.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  Behavioral Analysis of SNAP-25 and Synaptobrevin-2 Haploinsufficiency in Mice.

Authors:  Lisa M Monteggia; Pei-Yi Lin; Megumi Adachi; Ege T Kavalali
Journal:  Neuroscience       Date:  2018-08-23       Impact factor: 3.590

3.  Systems biology reveals reprogramming of the S-nitroso-proteome in the cortical and striatal regions of mice during aging process.

Authors:  Maryam Kartawy; Igor Khaliulin; Haitham Amal
Journal:  Sci Rep       Date:  2020-08-17       Impact factor: 4.379

4.  Role of Aberrant Spontaneous Neurotransmission in SNAP25-Associated Encephalopathies.

Authors:  Baris Alten; Qiangjun Zhou; Ok-Ho Shin; Luis Esquivies; Pei-Yi Lin; K Ian White; Rong Sun; Wendy K Chung; Lisa M Monteggia; Axel T Brunger; Ege T Kavalali
Journal:  Neuron       Date:  2020-11-03       Impact factor: 17.173

5.  The Putative Drosophila TMEM184B Ortholog Tmep Ensures Proper Locomotion by Restraining Ectopic Firing at the Neuromuscular Junction.

Authors:  Tiffany S Cho; Eglė Beigaitė; Nathaniel E Klein; Sean T Sweeney; Martha R C Bhattacharya
Journal:  Mol Neurobiol       Date:  2022-02-02       Impact factor: 5.682

6.  Levetiracetam Affects Differentially Presynaptic Proteins in Rat Cerebral Cortex.

Authors:  Daniele Marcotulli; Giorgia Fattorini; Luca Bragina; Jessica Perugini; Fiorenzo Conti
Journal:  Front Cell Neurosci       Date:  2017-12-11       Impact factor: 5.505

7.  Synaptic dysfunction induced by glycine-alanine dipeptides in C9orf72-ALS/FTD is rescued by SV2 replenishment.

Authors:  Brigid K Jensen; Martin H Schuldi; Kevin McAvoy; Katelyn A Russell; Ashley Boehringer; Bridget M Curran; Karthik Krishnamurthy; Xinmei Wen; Thomas Westergard; Le Ma; Aaron R Haeusler; Dieter Edbauer; Piera Pasinelli; Davide Trotti
Journal:  EMBO Mol Med       Date:  2020-04-29       Impact factor: 12.137

8.  The effect of NAMPT deletion in projection neurons on the function and structure of neuromuscular junction (NMJ) in mice.

Authors:  Samuel Lundt; Nannan Zhang; Xiaowan Wang; Luis Polo-Parada; Shinghua Ding
Journal:  Sci Rep       Date:  2020-01-09       Impact factor: 4.379

9.  ERICH3: vesicular association and antidepressant treatment response.

Authors:  Duan Liu; Yongxian Zhuang; Lingxin Zhang; Huanyao Gao; Drew Neavin; Tania Carrillo-Roa; Yani Wang; Jia Yu; Sisi Qin; Daniel C Kim; Erica Liu; Thanh Thanh Le Nguyen; Joanna M Biernacka; Rima Kaddurah-Daouk; Boadie W Dunlop; W Edward Craighead; Helen S Mayberg; Elisabeth B Binder; Mark A Frye; Liewei Wang; Richard M Weinshilboum
Journal:  Mol Psychiatry       Date:  2020-11-23       Impact factor: 13.437

10.  Presynaptic dysfunction in CASK-related neurodevelopmental disorders.

Authors:  Martin Becker; Francesca Mastropasqua; Jan Philipp Reising; Simon Maier; Mai-Lan Ho; Ielyzaveta Rabkina; Danyang Li; Janina Neufeld; Lea Ballenberger; Lynnea Myers; Viveka Moritz; Malin Kele; Josephine Wincent; Charlotte Willfors; Rouslan Sitnikov; Eric Herlenius; Britt-Marie Anderlid; Anna Falk; Sven Bölte; Kristiina Tammimies
Journal:  Transl Psychiatry       Date:  2020-09-14       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.